Browsing Tag
Remestemcel-L-rknd
2 posts
Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure
Mesoblast has reported higher year-on-year revenue from its approved cell therapy Ryoncil and a sharp reduction in operating cash expenditure, although sequential sales declined following a stronger June quarter.
Mesoblast stock gains as Ryoncil revenue hits US$115m in first launch year
Mesoblast Ryoncil revenue hits US$115m in its first launch year. Read how ASX:MSB’s biotech story is shifting from promise to sales.